Perioperative Encorafinib+Binimetinib in BRAFV600 Mutant Clinically Detected AJCC Stage III (B/C/D) or Oligometastatic Stage IV Melanoma
Latest Information Update: 13 May 2024
At a glance
- Drugs Binimetinib (Primary) ; Encorafenib (Primary) ; Antineoplastics
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms PREMIUM
- 10 May 2024 Planned End Date changed from 31 Jan 2024 to 28 Feb 2027.
- 10 May 2024 Status changed from active, no longer recruiting to recruiting.
- 21 Sep 2022 Status changed from not yet recruiting to recruiting.